Skip to content
AnalystLens

Colgate-Palmolive Annual Report, Year Ended Dec 31, 2003

Filing Date
Filed March 12, 2004
Period End
December 31, 2003
Security
CL
In the record · 2016–202610-K1210-Q338-K102

CL filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 102 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Oct ’17Oct ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Jun ’22Jun ’22
  4. Restructuring8-K · Oct ’25Oct ’25

Summary

Summary of the 10-K filed March 12, 2004. Cited figures are marked; the original filing is the authoritative source.

Colgate-Palmolive Company's 2003 10-K filing highlights a strong financial year characterized by consistent growth across its core segments: Oral, Personal, Household Surface and Fabric Care, and Pet Nutrition.

The company achieved a significant 6.5% increase in worldwide net sales, driven by a healthy 3.5% volume growth and a positive foreign exchange impact, underscoring its global brand strength and market penetration in over 200 countries. Profitability saw a notable increase, with operating profit rising 8% and net income growing to $1.42 billiona. This performance was supported by strategic cost-reduction initiatives, improved supply chain efficiencies leading to a higher gross profit margin, and a strategic focus on higher-margin businesses like Oral Care and Pet Nutrition.

The company also demonstrated strong cash flow generation, enabling increased dividend payments and share repurchases, while maintaining a robust credit rating. The planned acquisition of GABA Holding AG signaled a forward-looking strategy to further strengthen its leading position in the oral care market.

Key Highlights

  1. Worldwide net sales increased by 6.5% to $9.90 billion, driven by 3.5% volume growth and favorable foreign exchange of 2.5%.
  2. Operating profit grew by 8% to $2.17 billion, reflecting strong sales performance and cost-saving initiatives.
  3. Net income increased to $1.42 billion, or $2.46 per diluted share, up from $1.29 billion, or $2.19 per diluted share, in 2002.
  4. Gross profit margin improved to 55.0% from 54.6% in the prior year, driven by supply chain efficiencies and a focus on higher-margin products.
  5. The company announced an agreement to acquire GABA Holding AG, a European oral care company, to further bolster its oral care segment.
  6. Net cash provided by operations increased by 10% to $1.77 billion, supporting capital expenditures, dividends, and debt reduction.
  7. Advertising spending increased by 13% to support new product launches and market share growth globally.

Frequently Asked Questions

  1. What were the main drivers of Colgate-Palmolive's sales growth in 2003?

    Colgate-Palmolive's sales growth in 2003 was primarily driven by a combination of volume growth (3.5%), a positive foreign exchange impact (2.5%), and a slight increase in net selling prices (0.5%). The Oral, Personal, Household Surface and Fabric Care segment grew 6.0%, while the Pet Nutrition segment saw a robust 11.0% increase.

  2. How did the company manage its profitability and margins?

    The company improved its profitability through strategic cost-reduction initiatives across its supply chain, including global sourcing and manufacturing regionalization. This, along with a strategic focus on higher-margin businesses like Oral Care and Pet Nutrition, led to an improved gross profit margin of 55.0% and an 8% increase in operating profit.

  3. What is the significance of the planned acquisition of GABA Holding AG?

    The planned acquisition of GABA Holding AG, a European oral care company, is a strategic move to further strengthen Colgate-Palmolive's leading position in the global oral care market. This aligns with the company's strategy of prioritizing higher-margin businesses and expanding its product portfolio in key categories.

  4. How was the company's cash flow generation and what was it used for?

    Colgate-Palmolive demonstrated strong cash flow generation, with net cash provided by operations increasing by 10% to $1.77 billion. This cash was primarily used to fund capital expenditures, pay increased dividends to shareholders, repurchase common stock, and reduce overall debt levels.